Stayble has now enrolled and treated the first patient in the company's clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2505 SEK | +4.38% | +3.73% | -17.33% |
1st Jan change | Capi. | |
---|---|---|
-17.33% | 722K | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.37% | 21.83B | |
-10.67% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Enters the First Patient in Herniated Disc Study